Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. [electronic resource]
Producer: 20180521Description: 75 p. digitalISSN:- 2051-1426
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.